secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pharma-Bio Serv, Inc. (PBSV)
CIK:        0001304161
Form:       8-K
Filed at:   2023-09-14T23:59:59+00:00
Accession:  0001654954-23-011895
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pharma-Bio Serv Q3 net income up $0.2M to $0.5M; revenue down $0.2M to $4.6M
----------------------------------------------------------------------------

- Net income for Q3 FY2023 (three months ended July 31) was approx $0.5M, up from $0.3M YoY; nine-month net income $1.4M vs $0.9M.
- Q3 revenue $4.6M, down from $4.8M YoY; nine-month revenue $13.4M vs $14.8M.
- Gross profit margin improved 6.4 percentage points in Q3 and 5.3 percentage points YTD.
- CEO Sanchez highlighted successful strategy, new market expansion, and leveraging FDA scrutiny for profitability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1304161/000165495423011895/0001654954-23-011895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1304161/000165495423011895/pbsv_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-011895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer